Basic Attention Token vs Bio Protocol — how do they compare? Basic Attention Token trades at Rp1,028 (market cap Rp1,54T, Rp116,59M 24h volume), while Bio Protocol trades at Rp443.12 (market cap Rp1,01T, Rp176,29M 24h volume). The key difference: Basic Attention Token is the larger of the two by market cap, and Basic Attention Token's circulating supply is 1,5B / 1,5B BAT (100%) versus 2,3B / 3,3B BIO (69%) for Bio Protocol. Which is the better fit depends on your goals — on Pluang, investors hold Basic Attention Token for 91 Days and Bio Protocol for 18 Days on average.
| BAT | BIO | |
|---|---|---|
Market Cap | Rp1,54T | Rp1,01T |
Volume (24h) | Rp116,59M | Rp176,29M |
Circulating Supply | 1,5B / 1,5B BAT (100%) | 2,3B / 3,3B BIO (69%) |
Typical Hold Time | 91 Days | 18 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Bio Protocol (BIO) trades at Rp424.33 with a market cap of Rp965.85M, showing neutral technical signals amid bearish moving averages. The token's circulating supply of 2.3M out of 3.3M max indicates 69% circulation with an average hold time of 17 days. Recent technical indicators show mixed signals with RSI in neutral territory while ADX suggests some buying momentum. Support and resistance levels are well-defined between Rp398 and Rp500.
Overall outlook remains neutral with key opportunities in protocol adoption growth, though risks include limited liquidity and typical crypto volatility. Investors should monitor network activity closely as the token operates in a competitive blockchain ecosystem without major recent protocol updates.
What Pluang investors did over the last 30 days
BAT is an Ethereum-based token integrated into the privacy-focused web browser, Brave. The token is used as a payment method for running advertising campaigns through Brave Ads.
Read more on BAT →BIO Protocol enables global communities of scientists, patients, and investors to collectively fund, develop, and co-own new drugs and therapeutics through its network of Biotech Decentralized Autonomous Organizations (BioDAOs). The protocol's innovative approach addresses critical gaps in traditional scientific funding, particularly in areas such as rare diseases, longevity research, and emerging health challenges.
Read more on BIO →